Clinical Trial Update: Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) [Phase 1]

View source ↗

Summary

Phase 1 trial update of combining sorafenib with vorinostat in poor-risk acute myeloid leukemia and high-risk myelodysplastic syndromes. The study status is com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Promyelocytic Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Nexavar (Sorafenib)
• Zolinza (vorinostat)

Snippet

Sponsor: Indiana University School of Medicine | Conditions: Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute | Phase 1 | Status: COMPLETED